Genzyme Recognized by Scientists as a Top Employer

Genzyme CorporationGenzyme Corporation (Nasdaq: GENZ) has announced that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. This year Genzyme moved up in the ranking to third on the global list of nearly 500 companies, the highest ranking it has ever earned. Out of companies headquartered in New England Genzyme topped the list. This is the sixth year that Genzyme has placed among the top 10 of all biotechnology and pharmaceutical companies.

The survey, which was commissioned by Science magazine and the American Association for the Advancement of Science (AAAS), identified the top 20 companies with the best reputations as employers. More than 4,000 Science readers and other industry representatives participated in the survey. Genzyme earned the most votes in the following categories: innovative leader in the industry, a socially responsible company and having loyal employees.

"Our scientists are united by a common goal: to improve the lives of people who have serious diseases," said Alan Smith, Ph.D., senior vice president of research and chief scientific officer at Genzyme. "Because of their dedication and talent Genzyme will continue to develop breakthrough therapies."

About the Survey
Science and AAAS commissioned a web-based survey to determine the biotechnology and pharmaceutical companies with the best reputations as employers. For this year's survey, a mixed methodology was used. The first part of this methodology included e-mailed invitations to AAAS members, ScienceCareers.org registrants, and Science website visitors registered with AAAS. The second part of the methodology included an e-mail blast to more than 600 human resource contacts from the ScienceCareers.org database.

Survey respondents were asked to write in the names of companies they considered best, average and worst employers. They then rated these companies on 23 different attributes. Attribute categories included Corporate Image, Leadership and Direction, Financial Prowess, Work Culture/Environment, Work/Life Balance, Academics and Collegial Exchange, and Compensation and Benefits. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and more than 90 percent worked in private industry.

"We believe that promoting an environment that encourages employees to take risks and is socially responsible helps to foster employee loyalty and attract new talent," said Zoltan Csimma, senior vice president and chief human resources officer at Genzyme. "We are honored to be recognized as one of the top three companies in the world for scientists."

Genzyme is a leader in the effort to develop and apply the most advanced scientific technologies. Scientists working at Genzyme have developed novel treatments that are helping patients in more than 90 countries worldwide. The company is bringing new and next-generation therapies to patients with genetic diseases, kidney disease, cancer, osteoarthritis, as well as transplant and immune diseases. The company is also a leader in the development of diagnostic and genetic tests.

The survey results will appear in a special business supplement of the 10 October 2008 issue of Science.

For information about careers at Genzyme, please visit: http://www.genzyme.com/careers

About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...